Answers are grounded in this paper and cite their sources.
Angiogenesis in the central nervous system (CNS) is a context-dependent process whose dysregulation contributes to both brain tumors (as glioblastoma, GBM) and neurodegenerative diseases (NDs). In GBM, pro-angiogenic signaling promotes aberrant tumor vascularization, whereas in NDs it is associated with vascular dysfunction, blood–brain barrier disruption, and neuronal vulnerability. Despite these apparently opposite vascular phenotypes, both conditions share dysregulation of common pro-angiogenic signaling pathways, whose pathological effects are shaped by the distinct cellular and molecular microenvironments of each disease. In vitro models provide valuable tools to investigate these mechanisms under controlled experimental conditions and to evaluate disease-associated vascular responses and therapeutic strategies. This review summarizes current in vitro models of CNS angiogenesis and neurovascular dysfunction, with particular emphasis on the growing role of vascularization in the development of more physiologically relevant three-dimensional (3D) platforms. While two-dimensional (2D) models remain valuable for mechanistic studies and screening, they cannot fully reproduce the spatial organization and multicellular interactions of the neurovascular unit. Brain and tumor organoids have therefore emerged as particularly relevant human-based models, providing a 3D framework in which vascular, neural, tumor, and immune components can be integrated. We discuss organoids co-cultured with endothelial cells, vascularized organoids fusion, alongside microfluidic organ-on-chip and 3D bioprinted systems, highlighting their potential applications and current limitations. Overall, vascularized organoid-based models represent an important step toward more physiologically relevant models of CNS vascular pathology, enabling investigation of neurovascular and tumor–vascular interactions that may be difficult to fully reproduce in conventional systems. Further integration with perfusion, patient-specific human induced Pluripotent Stem Cells, and bioprinting may improve their predictive value for disease modeling and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Clelia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: